This path is for exploring information that is relevant to patients who are ALK positive “Only about 4% of lung cancers are ALK-positive. It most…

This course explores the efficacy of PD-1 Blockers within various cancer types.

This course explores the efficacy of Anti-PD1/PDL1 immunotherapy within various cancer types. “Despite advances in research, the prognosis of patients with cancer (particularly late-stage disease)…

This path is for exploring information that is relevant to Anti-TGIT Cancer Treatments.

This path is for exploring information that is relevant to Antibody-Drug conjugates (ADC) cancer treatments. “Antibody-drug conjugates (ADCs) are one of fastest growing classes of…

This path is for exploring research that is relevant to patients who have Castration Resistant Prostate Cancer. Castration-resistant prostate cancer (CRPC) is cancer that continues to…

This path is for exploring information that is relevant to patients who have shown the KRAS-G12C mutation “CEACAM5 is a cell surface glycoprotein that is…

Short timeline of when CTLA-4 Inhibitors were initially developed here Short Summary of development and some datapoints regarding CTLA-4 Inhibitors

This path is for exploring information that is relevant to patients who have show FGFR alterations. “Fibroblast growth factor receptors (FGFRs) are aberrantly activated through…

This path is for exploring information that is relevant to patients who have high levels of Androgen Receptors. AR can play a significant role in…

This path is for exploring information that is relevant to patients who have shown KRAS mutations. “KRAS mutations are present in approximately 25% of tumors,…

This path is for exploring information that is relevant to patients who have shown the KRAS-G12C mutation “KRAS G12C is an oncogenic driver mutation in multiple…

This path follows breakthrough research that shows that microbial bacteria can play a role in treating cancer. This path starts by exploring a study published in 2021 that found that 40% of non responders to a cancer therapy became responsive after given FMT.

This path is for exploring research around novel emerging combination therapies for the treatment of NSCLC.

This path is for exploring information that is relevant to TKI cancer treatments. “A substance that blocks the action of enzymes called tyrosine kinases. Tyrosine…